A series of first-in-class small molecular RhoA inhibitors:
Abstract
RhoA is a member of Rho GTPases, a subgroup of the Ras superfamily of small GTP-binding proteins.
RhoA, as an important regulator of diverse cellular signaling pathways, plays significant roles in cytoskeletal organization, transcription, and cell-cycle progression.
The RhoA/ROCK inhibitors have emerged as a new promising treatment for cardiovascular diseases.
However, to date, RhoA inhibitors are macromolecules, and to our knowledge, small molecular-based inhibitors have not been reported. In this study, a series of first-in-class small molecular RhoA inhibitors have been discovered by using structure-based virtual screening in conjunction with chemical synthesis and bioassay. Virtual screening of ∼200,000 compounds, followed by SPR-based binding affinity assays resulted in three compounds with binding affinities to RhoA at the micromolar level (compounds 1–3).
Compound 1 was selected for further structure modifications in considering binding activity and synthesis ease. Fourty-one new compounds (1, 12a–v, 13a–h, and 14a–j) were designed and synthesized accordingly. It was found that eight (12a, 12j, 14a, 14b, 14d, 14e, 14 g, and 14h) showed high RhoA inhibition activities with IC50 values of 1.24 to 3.00 μM. A pharmacological assay indicated that two compounds (14g and 14 h) demonstrated noticeable vasorelaxation effects against PE-induced contraction in thoracic aorta artery rings and served as good leads for developing more potent cardiovascular agents.
Citing Articles
View all 11 citing articles
Citation data is made available by participants in
CrossRef's Cited-by Linking service. For a more comprehensive list of citations to this article, users are encouraged to perform a search in
SciFinder.
This article has been cited by 2 ACS Journal articles (2 most recent appear below).
Lei Xu, Yu Zhang, Longtai Zheng, Chunhua Qiao, Youyong Li, Dan Li, Xuechu Zhen, and Tingjun Hou
Journal of Medicinal Chemistry2014 57 (9), 3737-3745
Discovery of Novel Inhibitors Targeting the Macrophage Migration Inhibitory Factor via Structure-Based Virtual Screening and Bioassays
LeiXu, YuZhang, LongtaiZheng, ChunhuaQiao, YouyongLi, DanLi, XuechuZhen, and TingjunHou
Journal of Medicinal Chemistry2014 57 (9), 3737-3745
Macrophage migration inhibitory factor (MIF) is involved in regulation of both the innate and the adaptive immune responses and is regarded as an attractive anti-inflammatory pharmacological target. In this study, molecular docking-based virtual screening ...
Tian Zhu, Shuyi Cao, Pin-Chih Su, Ram Patel, Darshan Shah, Heta B. Chokshi, Richard Szukala, Michael E. Johnson, and Kirk E. Hevener
Journal of Medicinal Chemistry2013 56 (17), 6560-6572
